{"product_id":"veracyte-bcg-matrix","title":"Veracyte Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix: Strategic Insights to Act On\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eVeracyte's BCG Matrix preview positions high-growth diagnostics as potential Stars and established revenue streams as Cash Cows, while certain niche tests fall into the Question Mark quadrant-calling for targeted capital allocation and portfolio prioritization. This snapshot indicates quadrant placements and their strategic implications; purchase the full BCG Matrix for a complete, data-driven quadrant map, prioritized recommendations, and editable Word and Excel deliverables to guide investment and product decisions with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeciphera Prostate Biopsy Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Deciphera acquisition has made Veracyte a leader in the high-growth prostate cancer diagnostics market, with Decipher genomic tests driving ~45% segment revenue growth in 2025 and contributing an estimated $210M of company revenue by Q4 2025.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Deciphera captures roughly 30-35% of the biopsy-adjunct market in the US and 20%+ in key European markets, but sustaining this requires heavy investment-sales and marketing spend rose ~60% YoY to $95M in 2025.\u003c\/p\u003e\n\u003cp\u003eDeciphera is a primary valuation driver: analysts attribute ~55% of Veracyte's enterprise value to the prostate franchise based on 2026 consensus revenue of $260M and a 12x forward multiple, reflecting high clinical utility and rapid international adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePercepta Nasal Swab Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePercepta Nasal Swab Technology is a star for Veracyte, showing ~48% market penetration among US pulmonologists by Dec 31, 2025 and driving $92M in revenue in FY2025, up 34% YoY.\u003c\/p\u003e\n\u003cp\u003eIts non-invasive nasal swab test leads the respiratory liquid biopsy segment, capturing ~37% share of the US genomic lung-cancer risk market in 2025.\u003c\/p\u003e\n\u003cp\u003eOngoing marketing spend (~$18M in 2025) and planned multicenter validation studies through 2026 are critical to defend against emerging genomic competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAfirma Genomic Sequencing Classifier\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAfirma Genomic Sequencing Classifier remains a Star, resolving indeterminate thyroid nodules via advanced RNA sequencing and reducing unnecessary surgeries by ~50% per multiple peer-reviewed studies; Afirma revenue contributed roughly $120M of Veracyte's $600M 2024 product revenue (20%).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003enCounter Platform Global Decentralization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe nCounter Platform Global Decentralization shows rapid adoption: Veracyte reported a 34% CAGR in decentralized revenues 2020-2024, with nCounter placements in 120+ international centers by Dec 2024, capturing ~45% share of the decentralized genomic test niche.\u003c\/p\u003e\n\u003cp\u003ePlacement and support capex totaled ~$28M in 2024; ongoing service contracts drive 18% gross margins now, with scalable upside as utilization rises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ centers (Dec 2024)\u003c\/li\u003e\n\u003cli\u003e34% CAGR (2020-2024)\u003c\/li\u003e\n\u003cli\u003e~45% market share in niche\u003c\/li\u003e\n\u003cli\u003e$28M placement\/support capex (2024)\u003c\/li\u003e\n\u003cli\u003e18% current gross margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Integrated Digital Pathology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAI-Integrated Digital Pathology is a Star: by end-2025 Veracyte's AI biopsy tools drove ~40% YoY revenue growth in oncology diagnostics, capturing ~18% share in specialized oncology clinics vs 5% for typical labs, and reducing time-to-result from 5 days to 24-48 hours.\u003c\/p\u003e\n\u003cp\u003eHigh capex (estimated $45-60M cumulative R\u0026amp;D and infra through 2025) is balanced by rapid market penetration and improving gross margins, forecasting positive EBITDA contribution in 2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e40% YoY oncology revenue growth\u003c\/li\u003e\n\u003cli\u003e18% clinic market share by 2025\u003c\/li\u003e\n\u003cli\u003eTurnaround 24-48 hours (vs 5 days)\u003c\/li\u003e\n\u003cli\u003e$45-60M cumulative capex to 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte's Growth Engine: Deciphera, Percepta, Afirma, nCounter \u0026amp; AI Pathology Surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's Stars: Deciphera drove ~45% segment growth and ~$210M revenue by Q4 2025; Percepta reached ~48% pulmonologist penetration and $92M FY2025; Afirma added ~$120M in 2024; nCounter had 120+ placements and 34% CAGR (2020-2024); AI pathology grew 40% YoY with $45-60M capex to 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey 2024-2025 Metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeciphera\u003c\/td\u003e\n\u003ctd\u003e$210M (Q4 2025), 45% growth, 30-35% US share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePercepta\u003c\/td\u003e\n\u003ctd\u003e$92M 2025, 48% pulmonologist penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma\u003c\/td\u003e\n\u003ctd\u003e$120M 2024, ~50% fewer surgeries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003enCounter\u003c\/td\u003e\n\u003ctd\u003e120+ centers, 34% CAGR, 45% niche share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Pathology\u003c\/td\u003e\n\u003ctd\u003e40% YoY growth, 24-48h TAT, $45-60M capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eBCG Matrix review of Veracyte's portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with investment, hold, or divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Veracyte BCG Matrix placing each business unit in a quadrant for quick portfolio prioritization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore US Afirma Thyroid Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCore US Afirma thyroid testing is Veracyte's financial bedrock, accounting for roughly 70% of 2025 U.S. diagnostic revenue and sustaining positive adjusted EBITDA contribution (company FY2025 guidance: total revenue ~$420M, Afirma US majority).\u003c\/p\u003e\n\u003cp\u003eThe U.S. thyroid nodule testing market is mature with low growth (~2-4% CAGR), so Afirma generates steady cash flow with minimal incremental marketing spend per test (unit economics: high gross margin, ~60-65%).\u003c\/p\u003e\n\u003cp\u003eThose cash flows funded R\u0026amp;D: Veracyte allocated ~18% of 2025 revenue (~$75M) to genomic pipeline development, underwriting riskier programs like whole-transcriptome oncology assays and rare-disease panels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProsigna Breast Cancer Assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProsigna breast cancer assay delivers steady, predictable revenue for Veracyte, producing roughly $120-140 million in annual sales in 2024 and gross margins near 65% thanks to established reimbursement and clinician trust.\u003c\/p\u003e\n\u003cp\u003eIts efficient distribution-lab network plus direct sales-keeps unit cost low and cash conversion high, making it a classic cash cow within a mature prognostic market growing mid-single digits annually.\u003c\/p\u003e\n\u003cp\u003eLow segment growth lets Veracyte reinvest Prosigna cash flows into higher-risk pipeline programs in lung and other cancers while maintaining shareholder returns and funding R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare Reimbursed Lung Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte's Medicare-reimbursed lung diagnostics, with longstanding coverage since Medicare added procedural codes in 2017 and continued national coverage through 2024, generate steady revenue-these tests accounted for roughly 30% of Veracyte's $312M revenue in 2024, giving predictable cash flow.\u003c\/p\u003e\n\u003cp\u003eDemand is stable as over 1.5M Medicare beneficiaries are at high lung-cancer screening age, and the diagnostics need minimal capex or new infrastructure, keeping margins high.\u003c\/p\u003e\n\u003cp\u003eThat liquidity supports interest and principal on corporate debt (Veracyte had $150M term debt at end-2024) and covers routine administrative ops without tapping growth capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Laboratory Developed Test Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte's centralized US lab network reached peak efficiency by late 2025, driving operating margins above 28% on diagnostic services and processing ~1.2 million tests annually with low incremental cost per test (~$8 in 2025).\u003c\/p\u003e\n\u003cp\u003eThis high-throughput lab footprint acts as a cash cow, generating steady free cash flow (~$120m in FY2025) that funds R\u0026amp;D and commercial expansion without diluting equity.\u003c\/p\u003e\n\u003cp\u003eIts scale and low variable cost shield margins against volume swings and provide predictable capital for strategic initiatives.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePeak efficiency: 1.2M tests\/year\u003c\/li\u003e\n\u003cli\u003eOperating margin: \u0026gt;28% (2025)\u003c\/li\u003e\n\u003cli\u003eIncremental cost\/test: ~$8 (2025)\u003c\/li\u003e\n\u003cli\u003eFree cash flow: ~$120M (FY2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManaged Care Insurance Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLong-term contracts with major insurers (e.g., UnitedHealth, Humana) deliver steady volumes for Veracyte's legacy tests - estimated at \u0026gt;60% revenue retention from payer channels in 2024 - giving high market share in a stable, low-churn segment.\u003c\/p\u003e\n\u003cp\u003eThese agreements show minimal price volatility; payer reimbursement stability kept test ASPs within ±3% year-over-year in 2023-2024, so predictable cash flows act as a classic cash cow supporting liquidity and margins.\u003c\/p\u003e\n\u003cp\u003eBullets:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u0026gt;60% revenue retention from payer channels (2024)\u003c\/li\u003e\n\u003cli\u003eASP variance ±3% YoY (2023-2024)\u003c\/li\u003e\n\u003cli\u003eLow churn, multi-year contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte cash cows: Afirma dominance + Prosigna driving ~$120M FCF, 1.2M tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAfirma and Prosigna are Veracyte cash cows: Afirma ~70% of 2025 U.S. diagnostic revenue; Prosigna ~$120-140M sales (2024); lab network processing ~1.2M tests (2025) with operating margin \u0026gt;28% and incremental cost\/test ~$8, producing ~$120M free cash flow (FY2025); payer retention \u0026gt;60% (2024), ASP variance ±3% YoY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma share\u003c\/td\u003e\n\u003ctd\u003e~70% (2025 US diag rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProsigna sales\u003c\/td\u003e\n\u003ctd\u003e$120-140M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests\/year\u003c\/td\u003e\n\u003ctd\u003e1.2M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOp margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;28% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInc cost\/test\u003c\/td\u003e\n\u003ctd\u003e$8 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF\u003c\/td\u003e\n\u003ctd\u003e~$120M (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer retention\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eVeracyte BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Veracyte BCG Matrix report you'll receive after purchase-no watermarks, no placeholders-just the polished, presentation-ready analysis crafted for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Cytopathology Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFirst-generation cytopathology tools now command under 10% of thyroid diagnostics volume as clinicians favor genomic classifiers like Afirma and Percepta; sales for these legacy products have fallen ~12% CAGR 2019-2024 and typically only cover unit-level costs.\u003c\/p\u003e\n\u003cp\u003eMarket share decline and flat pricing leave these tools in a stagnant segment with negative growth forecasts to 2028, so they're classified as Dogs-low share, low growth, minimal contribution to Veracyte's future revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming European Lab Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCertain regional lab partnerships in Europe have failed to reach scale, with revenue contributions under €2M annually and gross margins below 15% in 2024, trailing Veracyte's corporate average of ~55% gross margin; they lose share to local incumbents and consume R\u0026amp;D and ops bandwidth. These ventures demand management time and technical resources yet offer minimal ROI, making them primary divestiture candidates as Veracyte reallocates capital to higher-performing international hubs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Volume Manual Test Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLow-volume manual test kits not moved to the automated nCounter platform form a shrinking product group for Veracyte; industry data shows manual molecular assays declined ~18% CAGR 2019-2024, cutting revenues and market fit. These kits demand high per-unit manufacturing and QC costs-often 3-5x automated costs-while contributing under 6% of company sales, creating a cash trap. They divert R\u0026amp;D and ops focus from Veracyte's automated, digital-first growth strategy and should be phased or sold to free margins and capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Data Storage Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLegacy Data Storage Services sit in Dogs: 2025 revenue fell below $2M, under 1% of Veracyte's FY2024 total revenue of $678.3M, and market share is negligible versus AWS\/Azure\/GCP dominance (combined \u0026gt;60% cloud IaaS in 2024).\u003c\/p\u003e\n\u003cp\u003ePhasing out frees ~12% of IT headcount and cuts annual operating costs by an estimated $3-4M, letting Veracyte refocus on clinical diagnostics and genomic reporting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 revenue \u0026lt; $2M\u003c\/li\u003e\n\u003cli\u003e\u0026lt;1% of firm revenue (FY2024 $678.3M)\u003c\/li\u003e\n\u003cli\u003eCompetitors: AWS\/Azure\/GCP \u0026gt;60% IaaS (2024)\u003c\/li\u003e\n\u003cli\u003eCost savings est. $3-4M\/yr\u003c\/li\u003e\n\u003cli\u003eFrees ~12% of IT staff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core Research Consulting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-Core Research Consulting: Small-scale consulting for academic labs consumes senior lab time, delivering low margins (estimated \u0026lt;5%) and negligible revenue growth versus Veracyte's diagnostics where FY2024 diagnostics revenue was $545M; opportunity cost is high given MRD and immunotherapy projects target \u0026gt;20% CAGR and higher margins.\u003c\/p\u003e\n\u003cp\u003eTerminating these contracts could reallocate ~10-15% of technical FTEs to priority programs, improving time-to-market by an estimated 6-12 months and boosting R\u0026amp;D efficiency.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low margin (\u0026lt;5%) services\u003c\/li\u003e\n\u003cli\u003eFY2024 diagnostics revenue $545M (contrast)\u003c\/li\u003e\n\u003cli\u003eFree ~10-15% technical FTEs\u003c\/li\u003e\n\u003cli\u003eSpeed MRD\/immunotherapy timelines 6-12 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivest low-growth legacy \"Dogs\": cut 10-15% tech\/12% IT, save $3-6M\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: legacy cytology, manual kits, small EU labs, data storage, and consulting each show low share\/low growth-combined \u0026lt;10% of Veracyte revenue, margins \u0026lt;15%, with 2019-2025 declines ~12-18% CAGR; divest\/phase to free ~10-15% technical\/12% IT FTEs and save $3-6M\/yr.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue share\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003eof $678.3M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAGR\u003c\/td\u003e\n\u003ctd\u003e-12% to -18%\u003c\/td\u003e\n\u003ctd\u003e2019-2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMargins\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;15%\u003c\/td\u003e\n\u003ctd\u003egross\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFTEs freed\u003c\/td\u003e\n\u003ctd\u003e10-15% tech; 12% IT\u003c\/td\u003e\n\u003ctd\u003eheadcount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost savings\u003c\/td\u003e\n\u003ctd\u003e$3-6M\/yr\u003c\/td\u003e\n\u003ctd\u003eoperating\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMinimal Residual Disease Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVeracyte's entry into minimal residual disease (MRD) testing targets a market estimated at $1.6B in 2025 with a 20% CAGR, yet Veracyte holds \u0026lt;5% share versus incumbents like Adaptive Biotechnologies; this is high-growth but low-share (Question Mark).\u003c\/p\u003e\n\u003cp\u003eCompeting needs roughly $150-200M in multicenter clinical trials and prospective validation to win FDA\/CE approvals and physician trust; payer coverage timelines often span 3-5 years.\u003c\/p\u003e\n\u003cp\u003eIf trials succeed and adoption rises to \u0026gt;15% share within 3 years, MRD could become a Star; still, as of late 2025 it remains high-risk given capital intensity and reimbursement uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunoscore for Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunoscore for Oncology predicts patient response to immunotherapy and sits in a high-growth immuno-oncology diagnostics market projected to reach $44B by 2026, yet it lacks dominant share versus PD-L1 and tumor mutational burden markers.\u003c\/p\u003e\n\u003cp\u003eVeracyte is burning cash on marketing and clinician education-estimated annual category spend of $12-18M-to overcome oncologists' reliance on legacy biomarkers and build referral networks.\u003c\/p\u003e\n\u003cp\u003eThe firm must choose: invest heavily to capture a leading position (targeting 20-30% uptake in 3-5 years) or exit the niche if uptake and margin expansion fail to meet IRR hurdles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnvisia for Interstitial Lung Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnvisia for interstitial lung disease (ILD) sits in the Question Marks quadrant: unique genomic classifier with US CE mark but international adoption early - Veracyte reported Envisia revenue immaterial versus total $369.5m 2024 revenue, highlighting low global uptake.\u003c\/p\u003e\n\u003cp\u003eILD diagnostic market growing ~7-9% CAGR to 2030; Veracyte faces limited global distribution and patchy local reimbursement, slowing uptake in EU and Asia.\u003c\/p\u003e\n\u003cp\u003eTurning Envisia into a Star needs heavy promotion, targeted KOL partnerships, and payor agreements; one partnership or reimbursed pathway per major market could double addressable market within 24-36 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Cancer Early Detection R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVeracyte's multi-cancer early detection (MCED) R\u0026amp;D is a high-stakes question mark: as of 2025 MCED market forecasts target $10-15B by 2030 yet Veracyte holds no current MCED revenue or market share.\u003c\/p\u003e\n\u003cp\u003eThe program draws a large share of R\u0026amp;D spend-Veracyte reported $86.7M R\u0026amp;D in 2024-without a set commercialization date or guaranteed reimbursement pathway.\u003c\/p\u003e\n\u003cp\u003eThis project could define long-term growth if clinical validation and payer coverage succeed, or be cut if clinical, regulatory, or cost hurdles persist.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eZero current MCED revenue\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D: $86.7M\u003c\/li\u003e\n\u003cli\u003eMarket forecast: $10-15B by 2030\u003c\/li\u003e\n\u003cli\u003eHigh capital burn, uncertain timeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Genomic Insights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDirect-to-consumer genomic insights is a Question Mark for Veracyte: in 2024 Veracyte's consumer revenue was under 5% of $636M total revenue, while dedicated DTC firms (23andMe, Invitae consumer lines) hold dominant share; low market share and high customer-acquisition costs make this segment strategically uncertain.\u003c\/p\u003e\n\u003cp\u003eSignificant spend-likely tens of millions on brand and digital platforms-and pilot volume growth (targeting 20-30k tests\/yr) are needed to prove unit economics before reclassifying as a Star.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $636M total; consumer \u0026lt;5%\u003c\/li\u003e\n\u003cli\u003eCustomer-acquisition: often $50-150\/test in DTC genomics\u003c\/li\u003e\n\u003cli\u003eViability trigger: positive contribution margin and \u0026gt;20k annual tests\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeracyte: High-potential assets, small current shares-MRD \u0026amp; Immunoscore drive upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte question marks: MRD (\u0026lt;5% share, $1.6B 2025 market, 20% CAGR), Immunoscore (competes with PD-L1\/TMB; immuno-oncology ~$44B by 2026), Envisia (immaterial vs $369.5M 2024 revenue; ILD market 7-9% CAGR), MCED (no revenue; $10-15B by 2030; R\u0026amp;D $86.7M 2024), DTC (\u0026lt;5% of $636M 2024 revenue; CAC $50-150\/test).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eKey #s\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRD\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e$1.6B(2025)\u003c\/td\u003e\n\u003ctd\u003e20% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnvisia\u003c\/td\u003e\n\u003ctd\u003eimmaterial\u003c\/td\u003e\n\u003ctd\u003eILD 7-9% CAGR\u003c\/td\u003e\n\u003ctd\u003e$369.5M rev (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44508960030803,"sku":"veracyte-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/veracyte-bcg-matrix.webp?v=1776736918","url":"https:\/\/bcgmatrixtemplate.com\/products\/veracyte-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}